Novartis AG (NVSEF)
| Market Cap | 255.15B |
| Revenue (ttm) | 56.37B |
| Net Income (ttm) | 14.39B |
| Shares Out | n/a |
| EPS (ttm) | 7.30 |
| PE Ratio | 17.73 |
| Forward PE | 15.35 |
| Dividend | 3.97 (3.14%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 326 |
| Average Volume | 49,754 |
| Open | 126.62 |
| Previous Close | 126.31 |
| Day's Range | 126.62 - 126.62 |
| 52-Week Range | 94.70 - 137.39 |
| Beta | 0.44 |
| RSI | 48.97 |
| Earnings Date | Feb 4, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial StatementsNews
Price Over Earnings Overview: Novartis
In the current session, the stock is trading at $133.84, after a 1.06% spike. Over the past month, Novartis Inc. (NYSE: NVS) stock increased by 5.12% , and in the past year, by 30.63% . With performa...
Novartis upgraded at Morgan Stanley on stock pullback, Rhapsido launch
FIRST AID: Várhelyi backs Council stance on CMA
In today's edition: EPSCO special, biotech, Novartis
Novartis AG Social Impact & Sustainability Investor Event Transcript
Novartis AG Social Impact & Sustainability Investor Event Transcript
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy December 1, 2025 10:00 AM ESTCompany ParticipantsSteffen...
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy - Slideshow
2025-12-01. The following slide deck was published by Novartis AG in conjunction with this event.
Pre-Market Most Active for Nov 28, 2025 : TSLL, CRCG, IBIT, NVDA, BITF, ETHA, EPD, NIO, NVS, UL, CRCL, ORCL
The NASDAQ 100 Pre-Market Indicator is up 95.78 to 25,332.72. The total Pre-Market volume is currently 76,591,430 shares traded.The following are the most active stocks for the pre-market session: Dir...
Why Novartis Stock Topped the Market Today
It earned FDA approval for a spinal muscular atrophy drug. This is a version of its existing commercialized SMA treatment, Zolgensma.
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults
On Monday, the U.S. Food and Drug Administration (FDA) approved Novartis AG's (NYSE: NVS) Itvisma (onasemnogene abeparvovec-brve) for children two years and older, teens, and adults with spinal muscul...
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults
Novartis wins FDA approval for Itvisma, ... Full story available on Benzinga.com
Novartis (NVS) Gains FDA Approval for SMA Gene Therapy Itvisma
Novartis (NVS) Gains FDA Approval for SMA Gene Therapy Itvisma
Novartis plans to cut up to 550 jobs at Swiss facility
Novartis said on Tuesday up to 550 full-time jobs could be cut by the end of 2027 at the Swiss pharmaceutical company's Stein facility near Basel in northern Switzerland.
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
Basel, November 25, 2025 – Novartis will present data from over 70 abstracts, including investigator-initiated trials at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition and 2...
Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community
The only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA). The only gene replacement therapy for children two years and older, teens, and...
FDA Greenlights Novartis' (NVS) Itvisma for Wider SMA Patient Population
FDA Greenlights Novartis' (NVS) Itvisma for Wider SMA Patient Population
FDA approves Novartis' gene therapy for rare muscle disorder
U.S. Food and Drug Administration has approved Novartis' gene therapy for a type of rare muscle disorder, the drugmaker said on Monday.
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III s...
Novartis AG (NVS) Shareholder/Analyst Call Transcript
Novartis AG ( NVS) Shareholder/Analyst Call November 20, 2025 4:15 AM EST Company Participants Victor Bulto - President of US Angelika Jahreis - Global Head of Development Unit Immunology, Hepatology...
Novartis AG (NVS) Shareholder/Analyst Call Transcript
Novartis AG (NVS) Shareholder/Analyst Call November 20, 2025 3:00 AM ESTCompany ParticipantsSloan Simpson - Global Head of Investor RelationsVasant...
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
Novartis AG (NYSE: NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well int...
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
Novartis AG (NYSE: NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into...
Novartis Issues Updated Mid-term Sales Guidance; Upgrades Peak Sales Guidance For Kisqali, Scemblix
(RTTNews) - Novartis (NVS) announced its mid-term guidance to 2025-2030 of a sales CAGR of 5-6% cc. The company noted that the updated outlook follows upgrade of 2024-2029 guidance to 6% cc. Also, the...
Novartis (NVS) Projects Robust Growth with Updated Sales Guidance
Novartis (NVS) Projects Robust Growth with Updated Sales Guidance
Novartis Lifts Outlook With Stronger Peak Sales Forecasts
Novartis Lifts Outlook With Stronger Peak Sales Forecasts